Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pfizer Signs Pact For Drug Conjugates
by Michael McCoy
June 17, 2013
| A version of this story appeared in
Volume 91, Issue 24
Pfizer and CytomX Therapeutics are joining to develop antibody-drug conjugates (ADCs) using Probodies, antibodies from CytomX that remain inert in healthy tissue but are activated in the disease environment. CytomX is eligible for $25 million in up-front, research reimbursement, and preclinical milestone payments and up to $610 million in other milestone payments. Pfizer says the pact will help it advance the next generation of ADCs. Last month the firm revealed that an ADC failed in a Phase III clinical trial as a non-Hodgkin lymphoma treatment.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X